Wealth Enhancement Advisory Services
LRMR icon

Wealth Enhancement Advisory Services’s Larimar Therapeutics LRMR Stock Holding History

Wealth Enhancement Advisory Services’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$113K Sell
41,974
-21,706
-34% -$83.9K ﹤0.01% 3913
2026
Q2 		$273K Buy
63,680
+30,881
+94% +$123K ﹤0.01% 3292
2026
Q1 		$157K Buy
32,799
+17,185
+110% +$68.7K ﹤0.01% 3216
2025
Q4 		$52.6K Sell
15,614
-2,634
-14% -$10.2K ﹤0.01% 3531
2025
Q3 		$86.1K Buy
18,248
+4,619
+34% +$17.3K ﹤0.01% 3358
2025
Q2 		$43.6K Buy
+13,629
New +$31.6K ﹤0.01% 3242

Other funds holding LRMR

ACM
AIGH Capital Management Baltimore, Maryland $992M AUM 516.32% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Hennion & Walsh Asset Management
Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

Wealth Enhancement Advisory Services's LRMR Position: Q3 2026 in Review

Wealth Enhancement Advisory Services reduced its Larimar Therapeutics (LRMR) stake by 34% in Q3 2026, selling an estimated $83.9K and leaving 41,974 shares worth $113K. The position accounts for ﹤0.01% of the portfolio, ranked #3913.

Wealth Enhancement Advisory Services first reported a position in LRMR in Q2 2025 and has held it in 6 quarters since. The position peaked at $273K in Q2 2026. 62 funds tracked by Wall St. Rank hold LRMR as of Q3 2026.

  • Wealth Enhancement Advisory Services held 41,974 shares of Larimar Therapeutics worth $113K as of Q3 2026.
  • Wealth Enhancement Advisory Services sold 21,706 Larimar Therapeutics shares in Q3 2026, an estimated $83.9K.
  • Larimar Therapeutics made up ﹤0.01% of Wealth Enhancement Advisory Services's portfolio in Q3 2026, its #3913 holding.
  • Wealth Enhancement Advisory Services first reported a position in Larimar Therapeutics in Q2 2025 and has held it in 6 quarters since.
  • Wealth Enhancement Advisory Services's Larimar Therapeutics position peaked at $273K in Q2 2026.
  • 62 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q3 2026.

Based on Wealth Enhancement Advisory Services's 13F filing for Q3 2026, filed 13 Oct 2026.